Volume of injectate in patients experiencing transient neurologic adverse effects
Patient | Day 1 Volume (mL) | Day 2 Volume (mL) | Symptom/Sign |
---|---|---|---|
A | 20 | 31a | Syncope |
B | 33 | 41a | Autonomic disturbance |
C | 26 | 41a | Altered mental status |
D | 21 | 41a | Autonomic disturbance |
E | 27a | 52 | Syncope |
F | 61a | 31 | Vertigo |
G | 43a | 33 | Altered mental status |
↵a Occurrence of transient neurologic adverse effects.